filovirus
emerg
pathogen
caus
agent
viral
haemorrhag
fever
case
fatal
rate
filoviru
diseas
outbreak
among
highest
report
human
pathogen
exceed
ref
licens
therapeut
vaccin
product
avail
treat
filoviru
diseas
candid
therapeut
previous
shown
efficaci
nonhuman
primat
diseas
model
base
virusspecif
design
limit
broadspectrum
antivir
potenti
show
novel
synthet
adenosin
analogu
inhibit
infect
distinct
filovirus
human
cell
biochem
reporterbas
primerextens
assay
indic
inhibit
viral
rna
polymeras
function
act
nonoblig
rna
chain
termin
postexposur
intramuscular
administr
protect
ebola
viru
marburg
viru
diseas
rodent
model
importantli
complet
protect
cynomolgu
macaqu
marburg
viru
infect
administ
late
hour
infect
addit
exhibit
broadspectrum
antivir
activ
numer
virus
includ
bunyavirus
arenavirus
paramyxovirus
coronavirus
flavivirus
first
report
knowledg
nonhuman
primat
protect
filoviru
diseas
synthet
druglik
small
molecul
provid
addit
pharmacolog
character
support
potenti
develop
countermeasur
human
filoviru
diseas
viral
diseas
repres
major
public
health
threat
member
famili
filovirida
includ
ebola
viru
ebov
marburg
viru
marv
ravn
viru
ravv
sudan
viru
sudv
bundibugyo
viru
bdbv
caus
sever
viral
haemorrhag
fever
human
natur
filovirus
transmit
physic
contact
infect
individu
presum
via
infect
bodili
fluid
initi
filoviru
diseas
manifest
includ
fever
headach
vomit
diarrhoea
fatal
case
character
viraemia
elev
liverassoci
enzym
level
coagulopathi
haemorrhag
filoviru
diseas
outbreak
occur
sporad
frequent
subsaharan
africa
report
case
fatal
rate
exceed
ref
simultan
outbreak
involv
marv
sudv
bdbv
emerg
filoviru
isol
histor
occurr
independ
simultan
emerg
distinct
filovirus
highlight
need
identif
develop
efficaci
broadspectrum
antivir
product
although
licens
antivir
prevent
therapeut
agent
current
avail
combat
filoviru
diseas
human
number
candid
develop
evalu
nonhuman
primat
filoviru
diseas
model
model
close
reproduc
known
clinic
pathophysiolog
aspect
fatal
human
infect
nucleicacidbas
product
antibodi
therapi
therapeut
vaccin
success
protect
nonhuman
primat
filoviru
diseas
approach
reli
virusspecif
design
inher
limit
spectrum
activ
potenti
util
individu
treatment
develop
singl
therapeut
agent
activ
multipl
filovirus
would
provid
key
costeffect
compon
publichealth
prepared
plan
outbreakpron
region
broadspectrum
antivir
agent
ribavirin
trizol
nucleosid
effect
multipl
pathogen
rna
virus
activ
filovirus
small
moleculesinclud
adenosin
analogu
c
npc
favipiravir
substitut
pyrazin
compound
confer
highdegre
protect
filovirus
rodent
report
protect
nonhuman
primat
novel
nucleosid
analogu
fig
synthes
supplementari
inform
part
smallmolecul
librari
design
inhibitor
viral
rna
polymeras
activ
design
inhibit
viral
rna
polymeras
activ
indirectli
nonoblig
rna
chain
termin
mechan
requir
anabol
parent
compound
pyrophosph
cleavag
incorpor
nascent
viral
rna
strand
would
expect
caus
prematur
termin
transcript
replic
viral
rna
support
propos
mechan
rapidli
phosphoryl
cultur
cell
line
primari
hepatocyt
similar
natur
adenosin
nucleosid
fig
extend
data
fig
addit
reduc
express
green
fluoresc
protein
gfp
artifici
ebov
minigenom
replicon
assay
fig
extend
data
fig
virion
structur
protein
compris
viral
ribonucleoprotein
complex
mediat
transcript
replic
rna
replicon
templat
contain
gfpreport
cassett
inhibit
hepat
c
viru
hcv
rna
polymeras
transcript
activ
cellfre
isol
enzym
transcript
assay
fig
isol
filoviru
rna
polymeras
enzym
assay
yet
report
induc
prematur
termin
rna
chain
synthesi
hcv
rna
polymeras
templatedirect
primerextens
assay
fig
extend
data
fig
virusinfect
cell
reduc
surfaceexpress
marv
ebov
glycoprotein
reduc
product
intracellular
extracellular
marv
rna
fig
h
extend
data
fig
addit
hela
cell
incub
mm
produc
detect
infecti
marv
viru
concentr
provid
inhibit
ic
mm
fig
taken
togeth
assess
strongli
support
hypothesi
inhibit
viral
rna
polymeras
function
induc
rna
chain
termin
find
primerextens
reaction
suggest
termin
occur
two
base
incorpor
perhap
result
inhibitori
stereochem
distort
nascent
rna
chain
observ
evid
incorpor
human
rna
dna
expos
human
cell
concentr
exceed
marv
ic
tenfold
extend
data
fig
basi
select
viral
polymeras
yet
known
assess
spectrum
antivir
activ
conduct
addit
highcont
imag
hci
base
neutralr
uptak
antivir
assay
use
array
human
virus
exhibit
antivir
activ
negativesens
rna
virus
repres
filovirida
arenavirida
bunyavirida
orthomyxovirida
picornavirida
paramyxovirida
famili
positivesens
rna
virus
flavivirida
coronavirida
famili
tabl
extend
data
fig
antivir
effect
specif
result
cellular
toxic
antiprolif
effect
assess
enumer
live
cell
hci
assay
lactat
dehydrogenas
ldh
releas
assay
hela
cell
cytotox
concentr
cc
exceed
mm
determin
ldh
assay
consist
exceed
mm
use
hcibas
assay
tabl
antivir
effect
confirm
infect
human
macrophag
cultur
normal
peripher
blood
monocyt
use
ebov
extend
data
fig
import
note
immort
cell
line
exhibit
substanti
attenu
capac
convert
activ
tp
form
compar
primari
hepatocyt
extend
data
fig
thu
result
obtain
antivir
assess
reli
immort
cell
may
underrepres
antivir
potenc
achiev
vivo
experiment
clinic
infect
prepar
vivo
pharmacokinet
efficaci
test
sought
character
potenti
advers
pharmacolog
featur
could
limit
util
vivo
clinic
exhibit
mutagen
test
use
ame
assay
mg
per
plate
produc
detect
chromosom
aberr
human
lymphocyt
concentr
mm
inhibit
herg
ion
channel
current
mm
data
shown
compound
metabol
stabl
halflif
min
incub
liver
fraction
obtain
variou
anim
speci
extend
data
tabl
mous
rat
guinea
pig
cynomolgu
macaqu
pharmacokinet
character
rapid
clearanc
plasma
halflif
min
data
tabl
contrast
halflif
activ
form
liver
rat
substanti
longer
h
fig
rodent
model
filoviru
diseas
alway
reliabl
reproduc
pathophysiolog
observ
human
nonhuman
primat
nevertheless
rodent
system
provid
proofofconcept
efficaci
inform
dose
treatmentregimen
select
nonhuman
primat
efficaci
trial
ravvinfect
mice
intramuscular
im
administr
confer
high
degre
protect
group
treat
prophylact
dose
mg
kg
extend
data
fig
b
notabl
signific
protect
p
also
observ
dose
mg
kg
initi
time
long
h
infect
fig
addit
demonstr
mice
administ
either
im
oral
protect
lethal
ebov
challeng
mice
receiv
im
treatment
protect
lethal
rift
valley
fever
viru
challeng
extend
data
fig
vivo
postexposur
efficaci
verifi
two
guinea
pig
model
marv
diseas
anim
challeng
either
intraperiton
ip
inject
filovirus
transmit
via
aerosol
particl
exposur
aerosol
viru
ip
aerosolizedviru
challeng
model
confer
signific
postexposur
protect
treatment
initi
within
h
viru
exposur
extend
data
fig
respiratori
exposur
model
protect
guinea
pig
treatment
initi
delay
h
infect
longest
delay
test
extend
data
fig
explor
postexposur
efficaci
use
cynomolgu
macaqu
marv
diseas
model
accur
reproduc
filoviru
diseas
manifest
observ
fatal
human
case
cynomolgu
macaqu
experiment
infect
lethal
dose
wildtyp
marv
musok
variant
deriv
human
clinic
isol
anim
administ
mg
kg
twice
daili
im
inject
begin
h
infect
continu
day
six
infectioncontrol
subject
succumb
day
fig
develop
viraemia
fig
characterist
sign
filoviru
diseas
includ
behaviour
inact
maculopapular
rash
increas
liver
injuri
marker
aspart
aminotransferas
bilirubin
fig
prolong
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
fig
f
anim
treat
begin
h
infect
surviv
five
six
anim
treat
begin
h
infect
surviv
fig
consist
propos
antivir
mechan
action
significantli
substanti
reduc
serum
marv
burden
fig
without
induc
type
interferon
respons
extend
data
fig
observ
c
npc
mice
addit
amelior
haemorrhag
diseas
manifest
evidenc
shorter
pt
aptt
time
reduc
laboratori
indic
liver
damag
serum
ast
bilirubin
concentr
compar
vehicl
treatment
fig
outbreak
involv
marv
sudv
bdbv
report
uganda
democrat
republ
congo
highlight
urgent
need
develop
effect
antivir
product
counter
filoviru
diseas
first
time
knowledg
report
identif
small
molecul
efficaci
filoviru
diseas
nonhuman
primat
furthermor
provid
evid
exhibit
broadspectrum
antivir
activ
highli
virul
rna
virus
tabl
extend
data
fig
addit
evalu
progress
assess
vivo
efficaci
ebov
highli
virul
pathogen
nonhuman
primat
diseas
model
close
recapitul
human
diseas
well
toler
produc
overt
sign
system
toxic
advers
local
reaction
efficaci
studi
substanti
efficaci
observ
im
rout
provid
high
bioavail
rapid
absorpt
conduc
use
outbreak
potenti
enabl
administr
individu
lack
advanc
medic
train
marvinfect
cynomolgu
macaqu
observ
diminut
protect
effect
delay
treatment
initi
h
infect
suggest
even
greater
delay
treatment
yet
test
may
also
yield
signific
protect
benefit
prepar
advanc
human
phase
clinic
trial
unit
state
addit
studi
progress
support
file
investig
new
drug
applic
synthes
biocryst
pharmaceut
cellbas
infect
assay
conduct
use
hcibas
analys
describ
previous
filovirus
rift
valley
fever
viru
virus
inhibit
virusinduc
cytopath
effect
cpe
assess
cellbas
assay
use
neutralr
uptak
describ
previous
replic
ebov
minigenom
rna
construct
assay
use
plasmidbas
reconstitut
replicationtranscript
system
inhibit
rna
transcript
activ
assess
isol
hcv
polymeras
assay
inhibit
hcv
polymeras
rna
synthesi
activ
evalu
use
templatedriven
pgg
primer
extens
assay
mous
model
ebov
marv
ravv
diseas
describ
previous
experi
conduct
use
mouseadapt
strain
ebov
mayinga
variant
ravv
ravn
variant
guinea
pig
marvmusok
parenter
challeng
model
viru
aerosol
method
use
guinea
pig
exposur
previous
describ
administ
vehicl
steril
salin
inject
vivo
applic
anim
infect
experi
perform
biosafeti
level
contain
facil
unit
state
armi
medic
research
institut
infecti
diseas
usamriid
experiment
treatment
replic
conduct
use
biolog
replic
except
virusyield
reduct
assay
fig
reli
technic
replic
research
conduct
institut
anim
care
use
committe
approv
protocol
complianc
anim
welfar
act
ph
polici
feder
statut
regul
relat
anim
experi
involv
anim
facil
research
conduct
accredit
associ
assess
accredit
laboratori
anim
care
intern
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
